Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ascenta Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Ascenta Therapeutics Inc. thinks it has the right technology and team to make cancer a manageable disease. Its orally bioavailable small molecules are designed to hit key proteins mis-expressed in tumor cells-some of which are the targets of current biologics.

You may also be interested in...



Sanofi-Aventis To Co-Develop HDM2 Inhibitors For Cancer With Ascenta

Ascenta hopes to develop targeted cancer drugs that will be less toxic than standard chemotherapy and less expensive than biologics.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091281

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel